Deprescribing considerations for central nervous system‐active polypharmacy in patients with dementia

2024/11/26 by Anna Hung, Matthew E. Growdon · 1 citation
Medicine · Economics, Econometrics and Finance · #Pharmaceutical Practices and Patient Outcomes #Treatment of Major Depression #Health Systems, Economic Evaluations, Quality of Life

paper · pdf · doi:10.1111/jgs.19294

Abstract

See related article by Vordenberg et al .

Citations

• Effect of Central Nervous System Medication Use on Decline in Cognition in Community‐Dwelling Older Adults: Findings from the Health, Aging and Body Composition Study
• Associations Between Polypharmacy and Cognitive and Physical Capability: A British Birth Cohort Study
• American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults
• Clinician contributions to central nervous system‐active polypharmacy among older adults with dementia in the United States

Cited by

• Comprehensive Medication Reviews in Medicare Were Not Associated With Reduced Central Nervous System-Active Polypharmacy in 2021. [europepmc]

Related

• Rational Deprescribing in the Elderly
• Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary
• Polypharmacy and Deprescribing in Older Adults
• Clinician contributions to central nervous system‐active polypharmacy among older adults with dementia in the United States
• Medication deprescribing and its effects in polymedicated geriatric patients: a systematic review